Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 404

1.

Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.

Chopra A, Soni S, Verma D, Kumar D, Dwivedi R, Vishwanathan A, Vishwakama G, Bakhshi S, Seth R, Gogia A, Kumar L, Kumar R.

Asia Pac J Clin Oncol. 2015 Dec;11(4):293-8. doi: 10.1111/ajco.12400. Epub 2015 Aug 12.

PMID:
26264145
2.

A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.

Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS.

Leukemia. 2015 Aug;29(8):1668-75. doi: 10.1038/leu.2015.53. Epub 2015 Feb 27.

3.

Kaposi's sarcoma-associated herpesvirus microRNAs repress breakpoint cluster region protein expression, enhance Rac1 activity, and increase in vitro angiogenesis.

Ramalingam D, Happel C, Ziegelbauer JM.

J Virol. 2015 Apr;89(8):4249-61. doi: 10.1128/JVI.03687-14. Epub 2015 Jan 28.

4.

Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.

Ye YX, Zhou J, Zhou YH, Zhou Y, Song XB, Wang J, Lin L, Ying BW, Lu XJ.

Asian Pac J Cancer Prev. 2014;15(22):9961-6.

5.

The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.

Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ.

Curr Drug Targets. 2014;15(14):1322-30.

PMID:
25479544
6.

Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.

Jiang Q, Qin YZ, Lai YY, Jiang H, Wang J, Huang XJ.

Leuk Lymphoma. 2015 Jul;56(7):2075-81. doi: 10.3109/10428194.2014.982639. Epub 2015 Jan 14.

PMID:
25379619
7.

BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.

Zhu XS, Lin ZY, Du J, Cao GX, Liu G.

Asian Pac J Cancer Prev. 2014;15(12):4773-80.

8.

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T.

Leukemia. 2013 Nov;27(11):2253-4. doi: 10.1038/leu.2013.123. Epub 2013 Apr 22. No abstract available.

9.

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.

Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP.

BMC Cancer. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173.

10.

Tolerant anti-insulin B cells are effective APCs.

Kendall PL, Case JB, Sullivan AM, Holderness JS, Wells KS, Liu E, Thomas JW.

J Immunol. 2013 Mar 15;190(6):2519-26. doi: 10.4049/jimmunol.1202104. Epub 2013 Feb 8.

11.

Five most common prognostically important fusion oncogenes are detected in the majority of Pakistani pediatric acute lymphoblastic leukemia patients and are strongly associated with disease biology and treatment outcome.

Awan T, Iqbal Z, Aleem A, Sabir N, Absar M, Rasool M, Tahir AH, Basit S, Khalid AM, Sabar MF, Asad S, Ali AS, Mahmood A, Akram M, Saeed T, Saleem A, Mohsin D, Shah IH, Khalid M, Asif M, Haq R, Iqbal M, Akhtar T.

Asian Pac J Cancer Prev. 2012;13(11):5469-75.

12.

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J.

Blood. 2012 Oct 18;120(16):3382-3. doi: 10.1182/blood-2012-04-424192. No abstract available.

13.

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T.

Leukemia. 2013 Mar;27(3):629-34. doi: 10.1038/leu.2012.294. Epub 2012 Oct 9.

14.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group.

Blood. 2012 Sep 27;120(13):2573-80. Epub 2012 Aug 15.

15.

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE.

Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9.

PMID:
22772060
16.

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.

Takahashi N, Miura M, Scott SA, Niioka T, Sawada K.

J Hematol Oncol. 2012 May 15;5:23. doi: 10.1186/1756-8722-5-23.

17.

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, Giagounidis A, Stelljes M, Schmalzing M, Dührsen U, Wunderle L, Serve H, Brück P, Schmidt A, Hoelzer D, Ottmann OG.

Leukemia. 2012 Jul;26(7):1475-81. doi: 10.1038/leu.2012.5. Epub 2012 Jan 9.

PMID:
22230800
18.

Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.

Strhakova L, Bujalkova MG, Hojsikova I, Lukackova R, Behulova R, Mistrik M, Repiska V.

Neoplasma. 2011;58(6):548-53.

PMID:
21895409
19.

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

Soverini S, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M, Martinelli G.

Leuk Res. 2011 Nov;35(11):1527-9. doi: 10.1016/j.leukres.2011.05.029. Epub 2011 Jul 16.

PMID:
21762985
20.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12. No abstract available.

PMID:
21489624

Supplemental Content

Support Center